Close Menu

digital pathology

10x will develop a third genomics platform, possibly combining Cartana's more sensitive chemistry with ReadCoor's instrument.

The company reported on its development of a deep learning model to predict gene expression of tumors from whole slide images without the need to sequence RNA.

The company has developed a microscopy system that allows imaging of a full pathology slide in 21 channels with a single staining process and a rapid turnaround time.

The company plans to market  its GeoMx instruments for broader, more discovery-oriented research with a sequencing-based readout.

NanoString logged $30.6 million in revenues in the third quarter, beating the Wall Street estimate of $28.1 million.

The partners are preparing to release two updates to Navify Tumor Board that support automatic importation of structured Foundation Medicine test reports.

After slow, organic growth in imaging, the Spanish startup is courting major healthcare companies for a buyout as the genomics market presents major opportunities.

The firm reported that it expects product and service revenue of approximately $23.5 million for the fourth quarter of last year and $83.5 million for full-year 2018.

The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.

The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.

 

Pages

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.